# Integrated Computational Investigation of Cannabis sativa Phytoconstituents as Putative Multi-Target Inhibitors in Skin Cancer: A Molecular Docking, Dynamics, and ADMET Profiling Study

**Authors:** Lamiae El Bouamri, Salma Laaouina, Ibtissam Lakrim, Hassan Nour, Imane Yamari, Abdelouahid Samadi, Mohammed Bouachrine, Samir Chtita

PMC · DOI: 10.3390/ph19020315 · Pharmaceuticals · 2026-02-13

## TL;DR

This study explores how compounds from Cannabis sativa may inhibit key cancer pathways in skin cancer through computational methods.

## Contribution

The study identifies Cannabis sativa phytoconstituents as potential multitarget inhibitors for skin cancer signaling pathways.

## Key findings

- Several Cannabis sativa compounds showed strong binding affinities to EGFR, BRAF V600E, and TGF-β receptors.
- Molecular dynamics simulations confirmed stable protein-ligand interactions and favorable binding energetics.
- The compounds demonstrated good pharmacokinetic profiles and acceptable safety characteristics.

## Abstract

Background: Skin cancer progression is driven by the dysregulation of key oncogenic signaling pathways, including EGFR, BRAF V600E, and TGF-β, which collectively promote tumor proliferation, invasion, and metastatic progression. Targeting these pathways using multitarget natural modulators represents a promising therapeutic strategy. Methods: In this study, forty-nine phytoconstituents from Cannabis sativa were evaluated using an integrated computational approach to explore their inhibitory potential against EGFR, BRAF V600E, and the TGF-β receptor. Molecular docking was performed to assess binding affinities and interaction profiles, followed by ADMET analysis to evaluate pharmacokinetic and safety properties. The top-ranked compounds were further investigated using 200 ns molecular dynamics simulations and MM-GBSA binding free energy calculations to assess the stability and strength of protein–ligand interactions. Results: Several phytoconstituents exhibited strong binding affinities toward the target proteins, formed stable interactions with key active-site residues, and demonstrated favorable pharmacokinetic profiles with acceptable safety characteristics. Molecular dynamics simulations confirmed the structural stability of the selected protein–ligand complexes, while MM-GBSA analysis supported their favorable binding energetics. Conclusions: These findings suggest that Cannabis sativa phytoconstituents may represent a promising source of multitarget modulators capable of attenuating EGFR, BRAF V600E, and TGF-β driven oncogenic signaling in skin cancer. This study provides a mechanistic framework that supports further in vitro validation and the development of cannabis-derived therapeutic candidates for targeted skin cancer management.

## Linked entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956]
- **Diseases:** skin cancer (MONDO:0002898)
- **Species:** Cannabis sativa (taxon 3483)

## Full-text entities

- **Genes:** Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Braf (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 109880] {aka 9930012E13Rik, B-raf, Braf-2, Braf2, C230098H17, D6Ertd631e}, Egfr (epidermal growth factor receptor) [NCBI Gene 13649] {aka 9030024J15Rik, Erbb, Errb1, Errp, Wa5, wa-2}
- **Diseases:** metastasis (MESH:D009362), colorectal and lung cancer (MESH:D015179), carcinogenic (MESH:D011230), Toxicity (MESH:D064420), cutaneous oncological diseases (MESH:D000072716), Basal cell carcinoma (MESH:D002280), chronic (MESH:D002908), fibrosis (MESH:D005355), melanoma (MESH:D008545), inflammation (MESH:D007249), injury to (MESH:D014947), cancer (MESH:D009369), Skin Cancer (MESH:D012878), skin carcinogenesis (MESH:D063646), systemic diseases (MESH:D034721), Basal and squamous cell carcinomas (MESH:D002294)
- **Chemicals:** C5-C7 (-), Na+ (MESH:D012964), CBC (MESH:C010695), Cannabicyclol (MESH:C022213), Cl- (MESH:D002713), GLN (MESH:D005973), Erlotinib (MESH:D000069347), CBDA (MESH:C006884), CBGA (MESH:C100679), endocannabinoid (MESH:D063388), lipid (MESH:D008055), Hydrogen (MESH:D006859), LYS (MESH:D008239), Cannabinoid (MESH:D002186), CBD (MESH:D002185), flavonoids (MESH:D005419), PBSA (MESH:C437084), BE (MESH:D001608), salt (MESH:D012492), Delta9-THC (MESH:D013759), HIS (MESH:D006639), CBG (MESH:D002125), Vemurafenib (MESH:D000077484), Delta8-THC (MESH:C035731), water (MESH:D014867), Cannabinol (MESH:D002187), C6 (MESH:C117224), terpenes (MESH:D013729), Galunisertib (MESH:C557799), PHE A (MESH:C023037), Cannabigerol (MESH:C037036)
- **Species:** Homo sapiens (human, species) [taxon 9606], Cannabis sativa (species) [taxon 3483]
- **Mutations:** serine/threonine, V600E

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12944511/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944511/full.md

## References

82 references — full list in the complete paper: https://tomesphere.com/paper/PMC12944511/full.md

---
Source: https://tomesphere.com/paper/PMC12944511